Your session is about to expire
← Back to Search
Cannabinoid
Oral Cannabinoids for Chronic Pain
N/A
Recruiting
Led By Hance Clarke, MD, PhD
Research Sponsored by University Health Network, Toronto
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Age ≥ 25 years
Experiencing chronic, non-palliative pain
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 1 year
Awards & highlights
Study Summary
This trialis testing how well cannabis works to ease chronic pain and if it's safe. Results will inform a larger trial to study the same.
Who is the study for?
This trial is for adults over 25 who can read English and have chronic pain that isn't being managed by palliative care. It's not for those who've used cannabis products recently, have allergies to cannabinoids, serious health issues like heart or liver disease, uncontrolled mental disorders, are pregnant/breastfeeding, planning a family soon, or have alcohol/substance use disorder (except opioid use disorder).Check my eligibility
What is being tested?
The study tests the effectiveness and safety of medical cannabis in managing chronic pain. Over three months, participants will receive either CBD oil (MPL-001), a combination of CBD+THC oil (MPL-005), or a placebo to compare outcomes.See study design
What are the potential side effects?
Potential side effects may include dizziness, dry mouth, changes in appetite or mood swings associated with cannabinoid use. The specific side effects of MPL-001 and MPL-005 will be closely monitored throughout the trial.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am 25 years old or older.
Select...
I have long-term pain that is not just for comfort.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ through study completion, an average of 1 year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 1 year
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Feasibility outcome: pertaining to adherence to intervention
Feasibility outcome: pertaining to questionnaire data
Feasibility outcome: pertaining to the patients recruitment
+2 moreSecondary outcome measures
The mean Morphine Equivalent (MEQ) dose (mg/day) at 12 weeks post-treatment for patients that were consuming opioids at the start of the trial
The mean pain interference at 12 weeks post-treatment
Other outcome measures
Adverse events assessment
Assessment of symptoms of anxiety
Assessment of symptoms of depression
+3 moreTrial Design
3Treatment groups
Experimental Treatment
Placebo Group
Group I: CBD+THC oilExperimental Treatment1 Intervention
Participants will receive CBD (cannabidiol) oil in combination with THC (delta-9-tetrahydrocannabinol) for a total duration of 12 weeks.
Group II: CBD oilExperimental Treatment1 Intervention
Participants will receive CBD (cannabidiol) oil for a total duration of 12 weeks.
Group III: Placebo oilPlacebo Group1 Intervention
Participants will receive matching placebo oil for a total duration of 12 weeks.
Find a Location
Who is running the clinical trial?
University Health Network, TorontoLead Sponsor
1,475 Previous Clinical Trials
485,039 Total Patients Enrolled
12 Trials studying Chronic Pain
12,497 Patients Enrolled for Chronic Pain
Hance Clarke, MD, PhDPrincipal InvestigatorToronto General Hospital, UHN
4 Previous Clinical Trials
2,372 Total Patients Enrolled
2 Trials studying Chronic Pain
280 Patients Enrolled for Chronic Pain
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have not used nabilone, nabiximols, or cannabis in the last 30 days.I plan to start a family soon.I am 25 years old or older.I have not taken any pain medication before.You have a serious mental disorder like schizophrenia that is not under control.I do not have serious heart, lung, liver, or kidney diseases that would make treatment unsafe for me.I have long-term pain that is not just for comfort.I am currently taking Methadone or Buprenorphine.You have a problem with drinking too much alcohol or using drugs.
Research Study Groups:
This trial has the following groups:- Group 1: Placebo oil
- Group 2: CBD oil
- Group 3: CBD+THC oil
Awards:
This trial has 0 awards, including:Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
How many participants is the trial currently accepting?
"Affirmative. Clinicaltrials.gov contains evidence that this research is currently enrolling patients; it was first disseminated on November 22nd 2022 and has been updated as recently as the 28th of November. A total of 51 participants are required for this trial, taking place at a singular medical facility."
Answered by AI
Are volunteers being actively recruited for this research endeavor?
"Affirmative. Data hosted on clinicaltrials.gov confirms that the trial, which was first published 22 November 2022, is actively looking for participants. This research requires 51 patients from a single medical centre to join in its endeavour."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger